MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Biogen Company Profile (NASDAQ:BIIB)

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 9 Hold Rating(s), 16 Buy Rating(s)
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $341.67 (41.35% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$282.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Robert W. BairdReiterated RatingNeutral$268.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016HC WainwrightReiterated RatingBuy$360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016BMO Capital MarketsReiterated RatingMarket Perform$287.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper JaffrayReiterated RatingHold$293.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Citigroup Inc.DowngradeBuy -> Neutral$345.00 -> $295.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016Goldman SachsReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016JPMorgan Chase & Co.Reiterated RatingOverweight$403.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016BarclaysReiterated RatingBuy$420.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageNeutral$322.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Standpoint ResearchInitiated CoverageBuy$360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Raymond JamesReiterated RatingBuy$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015OppenheimerReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/22/2016        
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q414$3.77$4.09$2.64 billion$2.60 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214$2.81$3.49$2.14 billion$2.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.60$1.91ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2012$1.56$1.82ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012$1.49$1.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2012$1.49$1.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2011$1.52$1.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2011$1.36$1.36ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2011$1.41$1.43ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/1/2011$1.23$1.42ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Biogen (NASDAQ:BIIB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$3.82$4.71$4.40
Q2 20165$4.01$4.89$4.51
Q3 20165$4.13$4.99$4.59
Q4 20165$4.55$5.04$4.76
Q1 20171$4.87$4.87$4.87
Q2 20171$4.96$4.96$4.96
Q3 20171$4.98$4.98$4.98
Q4 20172$4.94$5.10$5.02
(Data provided by Zacks Investment Research)
Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Biogen (NASDAQ:BIIB)
DateHeadline
06/30/16 10:41 AMRecommendation Trends for: Biogen Inc. (NASDAQ:BIIB) - News Oracle
06/29/16 07:54 PMBiogen Inc. (BIIB) Pops 4.55% for June 29 - Equities.com
06/29/16 02:54 PMBiogen (BIIB) Stock Up as Bernstein Initiates Coverage -
06/29/16 02:24 PMThree Biotech Giants…But Only Two are Worth Buying -
06/29/16 11:23 AM4 Stocks, 4 trades: Monsanto's earnings miss -
06/29/16 05:08 AMCoverage initiated on Biogen by Bernstein -
06/28/16 08:08 PMBiotechnology: Biogen Inc. (NASDAQ:BIIB) Position of the day - Twin County News
06/28/16 03:02 PMBiogen : Selects Cognizant's SmartTrials Platform
06/28/16 12:35 PMSmart Chart Reading: Look For Solid Accumulation In A Base -
06/28/16 07:17 AMCovering the Bases on Biogen Idec Inc. (NASDAQ:BIIB): Where is the Stock Going? - Press Telegraph
06/28/16 07:17 AMSumitomo Mitsui Trust Holdings INC Decreased Stake in Biogen INC (NASDAQ:BIIB) by $10.03 Million as Shares ... - Engelwood Daily
06/28/16 07:17 AMShares in Decline this Year Biogen Inc. (NASDAQ:BIIB) - Press Telegraph
06/28/16 05:11 AMBiogen Selects Cognizant's SmartTrials Platform - [at noodls] - TEANECK, N.J., June 28, 2016/PRNewswire / -- Cognizant (NASDAQ: CTSH) today announced that Biogen (NASDAQ: BIIB) has selected Cognizant's SmartTrials™ platform to aggregate and store clinical trial operational ...
06/27/16 02:29 PMStrong Sell Calls Recommendations For Biogen Idec Inc. (NASDAQ:BIIB) At 0 - Investor Newswire
06/27/16 02:29 PMStock Touching a Recent Low: Biogen Inc. (NASDAQ:BIIB) - Press Telegraph
06/27/16 01:06 PMAlexion Pharmaceuticals: Brexit Be Damned; Citigroup Ups to Buy Citing "Dark Sky Valuation" -
06/27/16 09:29 AMIs Brexit Good for Biotech? Maybe -
06/26/16 02:41 PMHow Analysts Feel About Biogen Inc (NASDAQ:BIIB)? - Engelwood Daily
06/25/16 02:48 PMStock Performance Focus on: Biogen Inc. (NASDAQ:BIIB) - Press Telegraph
06/25/16 01:00 PMThink of This Stock as Buy-ogen -
06/24/16 02:51 PMShares Dropping to a Recent Low: Biogen Inc. (NASDAQ:BIIB) - Press Telegraph
06/24/16 06:34 AMClearbridge Investments LLC Decreased Stake in Biogen INC (NASDAQ:BIIB) by $27.16 Million as Shares Declined - Press Telegraph
06/23/16 10:17 PMM&A Hopes Trigger a Biogen Inc (BIIB) Bounce
06/23/16 04:23 PMBiogen Inc (BIIB): Growth at Risk? - Bidness ETC
06/23/16 03:39 PMBetter Buy: Biogen Inc. vs. Celgene Corporation -
06/22/16 07:58 PMTop Gainers of the Day: Biogen Inc. (NASDAQ:BIIB) from Biotechnology - Twin County News
06/22/16 02:48 PMHC Stocks News: Zoetis Inc (NYSE:ZTS), Biogen Inc (NASDAQ:BIIB) - share market updates (press release)
06/22/16 02:48 PMM&A Hopes Trigger a Biogen Inc (BIIB) Bounce - Schaeffers Research (blog)
06/21/16 04:43 PMWhy Biogen Inc. Is Down 22.5% In 2016 - Slowing sales growth for its multiple sclerosis drugs and a disappointing blow to its drug pipeline has caused shares to slide.
06/21/16 02:46 PMBiogen Idec Inc. (NASDAQ:BIIB): Growth Forecast - RealistInvestor.com
06/21/16 01:07 PMBiotech ETFs Reeling in Longest Sector Selloff in Two Decades -
06/21/16 07:36 AMBiogen Is The Ultimate Value Trap - Seeking Alpha
06/21/16 07:03 AMThese 5 Biotech Stocks Are Ridiculously Cheap -
06/20/16 03:19 PMBiogen to Report Second Quarter 2016 Financial Results on July 21, 2016 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the financial markets open. ... This ...
06/19/16 02:44 PMStrong Buy Calls Count For Biogen Idec Inc. (NASDAQ:BIIB) At 9 - Investor Newswire
06/17/16 06:00 AMBiogen Remains Undervalued -
06/16/16 08:13 PMHot Stock seeking Investors: Biogen Inc. (NASDAQ:BIIB) - News Oracle
06/16/16 02:51 PMRecent Trading Updates: Biogen Inc. (NASDAQ:BIIB) , Surgery Partners, Inc. (NASDAQ:SGRY) - Street Updates
06/16/16 07:04 AMWhy Now Is the Time to Buy Shares of Biogen -
06/15/16 02:53 PMAnalyst Overview on These 2 Stocks: Biogen Inc. (NASDAQ:BIIB), Cardinal Health, Inc. (NYSE:CAH) - Beacon Chronicle
06/15/16 07:39 AMHC Stocks Assessment: Celgene Corporation (NASDAQ:CELG), Biogen Inc (NASDAQ:BIIB) - share market updates (press release)
06/14/16 07:58 AMBiogen Becomes Oversold (BIIB)
06/13/16 10:51 AMStocks within Analysts Screening: Novavax, Inc. (NASDAQ:NVAX) , Biogen Inc. (NASDAQ:BIIB) - Street Updates
06/13/16 10:51 AMStock to Track: Biogen Inc. (NASDAQ:BIIB) - News Oracle
06/13/16 10:36 AMThe Neglected Biogen -
06/12/16 01:35 PMBiogen And Gilead Sciences Buck Biotech Short Interest Trend -
06/12/16 10:01 AMIs Biogen a Buy After its Clinical Failure? -
06/10/16 02:42 PMBiotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure -
06/10/16 10:03 AMWhat if Biogen Loses its Bet on More Pipeline Projects? -
06/09/16 03:26 PMBIOGEN INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
About Biogen

Biogen logoBiogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BIIB
  • CUSIP: 09062X10
Key Metrics:
  • Previous Close: $241.82
  • 50 Day Moving Average: $256.72
  • 200 Day Moving Average: $267.18
  • P/E Ratio: 14.86
  • P/E Growth: 1.62
  • Market Cap: $52.97B
  • Current Quarter EPS Consensus Estimate: $18.87 EPS
Additional Links:
Biogen (NASDAQ:BIIB) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha